DNA Nanobots to Target Cancer Cells in First Human Trial

Life Science Investing News

3Tags reported that Professor Ido Bachelet of Israel’s Bar-Ilan University confirmed that nanobots capable of fighting cancerous cells no longer a thing of science fiction.

3Tags reported that Professor Ido Bachelet of Israel’s Bar-Ilan University confirmed that nanobots capable of fighting cancerous cells no longer a thing of science fiction. Indeed, the first DNA nanobot trial in a human subject will take place in 2016.
According to the report:

Nanobots can also have multiple “payloads” in them, and can be programmed so that they know which drug to expose to specific molecules. This means that nanobots work well in combination therapy—where multiple drugs are used at once—and can be timed so that the different drugs don’t interfere with one another. As of December 2014, the nanobots that Bachelet’s team have developed can recognize 12 different types of cancerous cells.

3Tags also notes that:

In that case, when can we expect this miracle treatment to hit the public? The first DNA nanobot trial in a human subject will take place this year—in fact, it could be happening right now—on a person with late-stage leukemia. The patient is expected to die, but Bechelet believes that, based on previous animal trials, the nanobots can remove the cancer in the span of a month. If the trial goes well, we could see nanotechnology hit the public in one-to-five years.”

 

Click here to view the full article. 

The Conversation (2)
Huy Lam
Huy Lam
27 Nov, 2017
Please let me know where I can access this treatment. And how to invest in this chanel
Huy Lam
Huy Lam
27 Nov, 2017
Please let me know where I can access this treatment. And how to invest in this chanel
×